A Phase 1 interventional study of MK0524B (ER niacin (+) laropiprant (+) simvastatin) and MK0524A (ER niacin + laropiprant) in Dyslipidemia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-19.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Dyslipidemias by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Dyslipidemias · Merck & Co., Inc.
Among the 26 studies in Dyslipidemias by Merck & Co., Inc, this one is the 11th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2007, is one of 9 in phase 1, and was the 11th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →None of the 26 studies in Dyslipidemias by Merck & Co., Inc is open now. The open studies under Dyslipidemias, anywhere →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 190 across the 24 interventional studies, 328 across the 2 observational. Of the 25 that completed or were terminated, 13 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Dyslipidemias by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Period 1: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg). Period 2: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets.
Drug: MK0524B (ER niacin (+) laropiprant (+) simvastatin) · Drug: MK0524A (ER niacin + laropiprant) · Drug: Simvastatin
Period 1: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets. Period 2: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg).
Drug: MK0524B (ER niacin (+) laropiprant (+) simvastatin) · Drug: MK0524A (ER niacin + laropiprant) · Drug: Simvastatin
Drug page: MK-0524B
Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.
Also known as: MK0524B
Drug page: MK-0524A
Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods.
Also known as: MK0524A
Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.
Also known as: Zocor™
Plasma Area Under the Curve (AUC(0 to 48hr)) for Simvastatin Acid
Plasma Area Under the Curve of simvastatin acid, the active metabolite of simvastatin
Time frame: Through 48 Hours Post Dose
Peak Plasma Concentration (Cmax) of Simvastatin Acid
Peak Plasma Concentration (Cmax) for Simvastatin Acid, the active metabolite of simvastatin
Time frame: 48 Hours Post Dose
Plasma Area Under the Curve (AUC(0 to 48 Hour)) for Simvastatin
Plasma Area Under the Curve of simvastatin
Time frame: Through 48 Hours Post Dose
Peak Plasma Concentration (Cmax) of Simvastatin
Time frame: 48 Hours Post Dose
Plasma Area Under the Curve (AUC(0 to Infinity)) for Laropiprant
Plasma Area Under the Curve of Laropiprant
Time frame: 48 Hours Post Dose
Peak Plasma Concentration (Cmax) of Laropiprant
Time frame: 48 Hours Post Dose
Peak Plasma Concentration (Cmax) of Nicotinuric Acid
Peak Plasma Concentration (Cmax) for Nicotinuric Acid, one of the active metabolites of Niacin
Time frame: 24 Hours Post Dose
Total Urinary Excretion of Niacin and Its Metabolites
Time frame: 96 Hours Post Dose
| Milestone | MK0524B Then Simvastatin + MK0524A | Simvastatin + MK0524A Then MK0524B |
|---|---|---|
| Started | 110 | 110 |
| Completed | 108 | 108 |
| Not completed | 2 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Did not follow study procedures | 1 | 0 |
| Withdrew: Personal reasons | 0 | 1 |
| Milestone | MK0524B Then Simvastatin + MK0524A | Simvastatin + MK0524A Then MK0524B |
|---|---|---|
| Started | 108 | 108 |
| Completed | 108 | 108 |
| Not completed | 0 | 0 |
Plasma Area Under the Curve of simvastatin acid, the active metabolite of simvastatin
| ng/mL * Hour | MK0524B | Simvastatin + MK0524A |
|---|---|---|
| Plasma Area Under the Curve (AUC(0 to 48hr)) for Simvastatin Acid | 9.19 ± 8.38 | 8.03 ± 7.78 |
Peak Plasma Concentration (Cmax) for Simvastatin Acid, the active metabolite of simvastatin
| ng/mL | MK0524B | Simvastatin + MK0524A |
|---|---|---|
| Peak Plasma Concentration (Cmax) of Simvastatin Acid | 1.016 ± 0.946 | 0.918 ± 0.906 |
Plasma Area Under the Curve of simvastatin
| ng/mL * Hour | MK0524B | Simvastatin + MK0524A |
|---|---|---|
| Plasma Area Under the Curve (AUC(0 to 48 Hour)) for Simvastatin | 15.03 ± 9.88 | 15.56 ± 9.11 |
| ng/mL | MK0524B | Simvastatin + MK0524A |
|---|---|---|
| Peak Plasma Concentration (Cmax) of Simvastatin | 5.81 ± 4.31 | 6.33 ± 4.64 |
Plasma Area Under the Curve of Laropiprant
| nmol/L * hour | MK0524B | Simvastatin + MK0524A |
|---|---|---|
| Plasma Area Under the Curve (AUC(0 to Infinity)) for Laropiprant | 5486 ± 2832 | 5405 ± 2618 |
| nmol/L | MK0524B | Simvastatin + MK0524A |
|---|---|---|
| Peak Plasma Concentration (Cmax) of Laropiprant | 1030 ± 642 | 953 ± 542 |
Peak Plasma Concentration (Cmax) for Nicotinuric Acid, one of the active metabolites of Niacin
| ng/mL | MK0524B | Simvastatin + MK0524A |
|---|---|---|
| Peak Plasma Concentration (Cmax) of Nicotinuric Acid | 620 ± 536 | 807 ± 469 |
| µmol | MK0524B | Simvastatin + MK0524A |
|---|---|---|
| Total Urinary Excretion of Niacin and Its Metabolites | 5339 ± 968 | 5825 ± 1188 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK0524B | — | 0/220 (0%) | 61/220 (27.7%) |
| Simvastatin + MK0524A | — | 0/220 (0%) | 58/220 (26.4%) |
| Event | MK0524B | Simvastatin + MK0524A |
|---|---|---|
| HeadacheNervous system disorders | 9/220 | 17/220 |
| FlushingVascular disorders | 8/220 | 17/220 |
| NauseaGastrointestinal disorders | 15/220 | 12/220 |
| Abdominal PainGastrointestinal disorders | 7/220 | 3/220 |
| PruritusSkin and subcutaneous tissue disorders | 7/220 | 3/220 |
| ConstipationGastrointestinal disorders | 6/220 | 2/220 |
| VomitingGastrointestinal disorders | 3/220 | 5/220 |
| DiarrhoeaGastrointestinal disorders | 4/220 | 2/220 |
| Back PainMusculoskeletal and connective tissue disorders | 4/220 | 0/220 |
| ParaesthesiaNervous system disorders | 4/220 | 3/220 |
| Age, Continuous(years) | Overall Study Population |
|---|---|
| Mean | 35.11 (18 to 65) |
| Sex: Female, Male(Participants) | Overall Study Population |
|---|---|
| Female | 92 |
| Male | 128 |
| Height(Centimeters) | Overall Study Population |
|---|---|
| Mean | 169.58 (147 to 193) |
| Weight(Kilograms) | Overall Study Population |
|---|---|
| Mean | 72.99 (43.6 to 111.2) |
No study locations are listed for this record.
The record gives a start of Jul 2007, a primary completion of Aug 2007 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: MK-0524B · MK-0524A · Simvastatin